{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:40:31Z","timestamp":1790822431804,"version":"4.1.0"},"reference-count":57,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The discovery of neoantigens and their application in cancer vaccines have brought about a paradigm shift in cancer immunotherapy, similar to the way in which immune checkpoint inhibitors redefined therapeutic strategies for cancer treatment. Early neoantigen vaccine approaches primarily focused on eliciting HLA class I-restricted CD8+ cytotoxic T lymphocyte (CTL) responses, whereas it has become clear that such strategies alone may be insufficient to establish durable and effective antitumor immunity. Increasing attention has therefore shifted toward HLA class II-restricted neoantigens (\u201chelper neoantigens\u201d) that activate tumor-specific CD4+ helper T cells. Recent studies have revealed that neoantigen-reactive CD4+ helper T cells play a central role in coordinating antitumor immune responses through dendritic cell licensing, thereby sustaining CD8+ CTL function, preventing T-cell exhaustion, and promoting the generation of long-lived memory T cells. These findings have highlighted the pivotal role of helper neoantigens in shaping vaccine efficacy. In this review, we discuss the mechanistic basis underlying the contribution of helper neoantigens to tumor immunity and highlight recent advances in the real-world application of helper neoantigen-based vaccine strategies.<\/jats:p>","DOI":"10.3390\/cancers18152461","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:20:18Z","timestamp":1785486018000},"page":"2461","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Central Role of HLA Class II-Restricted Helper Neoantigen Vaccines in Cancer Immunotherapy"],"prefix":"10.3390","volume":"18","author":[{"given":"Takafumi","family":"Morisaki","sequence":"first","affiliation":[{"name":"Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic, Fukuoka 812-0018, Japan"},{"name":"Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Morisaki","sequence":"additional","affiliation":[{"name":"Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic, Fukuoka 812-0018, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer neoantigens","volume":"37","author":"Schumacher","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","article-title":"Genomic correlates of response to immune checkpoint blockade","volume":"25","author":"Keenan","year":"2019","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41586-023-05787-1","article-title":"Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy","volume":"615","author":"Sennino","year":"2023","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining T cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Busselaar, J., Tian, S., van Eenennaam, H., and Borst, J. (2020). Helpless priming sends CD8+ T cells on the road to exhaustion. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.592569"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer: Mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: Insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumor immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/JLB.5RI0220-603RR","article-title":"Harnessing neoantigen specific CD4 T cells for cancer immunotherapy","volume":"107","author":"Brightman","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/1074-7613(95)90078-0","article-title":"A unique tumor antigen produced by a single amino acid substitution","volume":"2","author":"Monach","year":"1995","journal-title":"Immunity"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6057","DOI":"10.4049\/jimmunol.172.10.6057","article-title":"T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product","volume":"172","author":"Huang","year":"2004","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"Riaz","year":"2017","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kaczmarek, M., Pozna\u0144ska, J., Fechner, F., Michalska, N., Paszkowska, S., Napiera\u0142a, A., and Mackiewicz, A. (2023). Cancer vaccine therapeutics: Limitations and effectiveness\u2014A literature review. Cells, 12.","DOI":"10.3390\/cells12172159"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41541-025-01118-9","article-title":"Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer","volume":"10","author":"Shah","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.immuni.2017.10.009","article-title":"CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness","volume":"47","author":"Ahrends","year":"2017","journal-title":"Immunity"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e174027","DOI":"10.1172\/jci.insight.174027","article-title":"CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy","volume":"8","author":"Huff","year":"2023","journal-title":"JCI Insight"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41590-023-01543-9","article-title":"Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors","volume":"24","author":"Brightman","year":"2023","journal-title":"Nat. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","article-title":"Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses","volume":"184","author":"Cui","year":"2021","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41467-022-35615-5","article-title":"CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment","volume":"14","author":"Lei","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nri.2015.10","article-title":"The multifaceted role of CD4+ T cells in CD8+ T cell memory","volume":"16","author":"Laidlaw","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ccell.2022.03.006","article-title":"Neoantigen-Specific CD4+ T Cells in Human Melanoma Have Diverse Differentiation States and Correlate with CD8+ T Cell, Macrophage, and B Cell Function","volume":"40","author":"Veatch","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0264-410X(02)00534-0","article-title":"Dendritic cell KLH loading requirements for efficient CD4+ T-cell priming and help to peptide-specific cytotoxic T-cell response, in view of potential use in cancer vaccines","volume":"21","author":"Millard","year":"2003","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"200835","DOI":"10.1016\/j.omton.2024.200835","article-title":"Neoantigen-specific T cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer","volume":"32","author":"Pesic","year":"2024","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Morisaki, S., Onishi, H., Morisaki, T., Kubo, M., Umebayashi, M., Tanaka, H., Koya, N., Nakagawa, S., Tsujimura, K., and Yoshimura, S. (2023). Immunological analysis of hybrid neoantigen peptide encompassing class I\/II neoepitope-pulsed dendritic cell vaccine. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1223331"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Morisaki, T., Kubo, M., Morisaki, S., Umebayashi, M., Tanaka, H., Koya, N., Nakagawa, S., Tsujimura, K., Yoshimura, S., and Kiyotani, K. (2024). Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer. Cancers, 16.","DOI":"10.3389\/fimmu.2025.1565696"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e164258","DOI":"10.1172\/JCI164258","article-title":"Linked CD4+\/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression","volume":"133","author":"Dolina","year":"2023","journal-title":"J. Clin. Invest."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e20250025","DOI":"10.1084\/jem.20250025","article-title":"Chimeric MHC Class I- and II-Restricted Non-Self Epitopes Broaden Antitumor T Cell Reactions","volume":"223","author":"Zhang","year":"2026","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Oyama, K., Nakata, K., Abe, T., Hirotaka, K., Fujimori, N., Kiyotani, K., Iwamoto, C., Ikenaga, N., Morisaki, S., and Umebayashi, M. (2025). Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: A retrospective study. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1571182"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e1328341","DOI":"10.1080\/2162402X.2017.1328341","article-title":"Trial watch: Dendritic cell-based anticancer immunotherapy","volume":"6","author":"Garg","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.trecan.2017.12.007","article-title":"Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment","volume":"4","author":"Saxena","year":"2018","journal-title":"Trends Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2412876","DOI":"10.1080\/2162402X.2024.2412876","article-title":"Trial watch: Anticancer vaccination with dendritic cells","volume":"13","author":"Borges","year":"2024","journal-title":"Oncoimmunology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","article-title":"Personalized neoantigen-pulsed dendritic cell vaccine for advanced lung cancer","volume":"6","author":"Ding","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s10038-021-00950-w","article-title":"Immunogenomics in personalized cancer treatments","volume":"66","author":"Kiyotani","year":"2021","journal-title":"J. Hum. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Morisaki, T., Morisaki, T., Kubo, M., Morisaki, S., Nakamura, Y., and Onishi, H. (2022). Lymph Nodes as Anti-Tumor Immunotherapeutic Tools: Intranodal-Tumor-Specific Antigen-Pulsed Dendritic Cell Vaccine Immunotherapy. Cancers, 14.","DOI":"10.3390\/cancers14102438"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cai, Y., Chen, R., Gao, S., Li, W., Liu, Y., Su, G., Song, M., Jiang, M., Jiang, C., and Zhang, X. (2023). Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1054231"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Zhao, P., Effenberger, C., Matsumoto, S., Morisaki, T., Ishii, Y., Umebayashi, M., Tanaka, H., Koya, N., Nakagawa, S., and Tsujimura, K. (2026). Profiling immunogenic neoantigen peptides elicited by personalized neoantigen vaccine in cancer patients. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1829509"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41568-025-00832-9","article-title":"Regulatory T cells in the tumour microenvironment","volume":"25","author":"Imianowski","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1158\/0008-5472.CAN-11-3912","article-title":"Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: A current perspective","volume":"72","author":"Le","year":"2012","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-024-07752-y","article-title":"Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy","volume":"632","author":"Sultan","year":"2024","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Dhatchinamoorthy, K., Colbert, J.D., and Rock, K.L. (2021). Cancer immune evasion through loss of MHC class I antigen presentation. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.636568"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Shklovskaya, E., and Rizos, H. (2021). MHC class I deficiency in solid tumors and therapeutic strategies to overcome it. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136741"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ccell.2026.04.002","article-title":"Bridging Clinical Gaps in Personalized Cancer Neoantigen Vaccines","volume":"44","author":"Khaddour","year":"2026","journal-title":"Cancer Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2461\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:34:00Z","timestamp":1785486840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":57,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152461"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152461","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]}}}